ERCP Clinical Trial - Drotaverine Hydrochloride Versus

Status Completed

Clinical Trial Summary

The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.

Clinical Trial Description

ERCP is an important endoscopic technique in the diagnosis and treatment of pancreatic and biliary diseases. Duodenal peristalsis can make cannulation of the papilla and the necessary therapeutic procedures difficult. Intravenous hyoscine-N-butylbromide is often used during ERCP to inhibit duodenal motility and enhance cannulation in China. However, the pharmaceutical agent is occasionally associated with serious complications such as cardiovascular events or anaphylactic shock. Hyoscine-N-butylbromide may also affect the ocular, urinary, and salivary systems.

Drotaverine hydrochloride is an analogue of papaverine with smooth muscle relaxant properties. It is a non-anticholinergic antispasmodic, which selectively inhibits phosphodiesterase IV and is accompanied by a mild calcium channel-blocking effect. Adverse effects with drotaverine hydrochloride, such as hypotension, vertigo, nausea, and palpitation, are mostly mild. It can be supposed that intravenous drotaverine hydrochloride might be a feasible antimotility alternative to intravenous hyoscine-N-butylbromide in ERCP. But there is no clear evidence to recommend the use of drotaverine hydrochloride as an antispasmodic during ERCP.

The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP. The effects of drotaverine hydrochloride on facilitative cannulation and its adverse effects were also compared to hyoscine-N-butylbromide. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00731198
Study type	Interventional
Source	Changhai Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	August 2008
Completion date	July 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04205058` - Coffee After Pancreatic Surgery	N/A
Completed	`NCT02971579` - A Register on the Quality of ERCP and Training of Endoscopists in Italy
Not yet recruiting	`NCT01900938` - Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP	N/A
Completed	`NCT01427725` - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Not yet recruiting	`NCT05954221` - Red Cell Lysis Buffer Application Versus Conventional Sample Processing in EUS-FNB	N/A
Enrolling by invitation	`NCT02471170` - Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
Completed	`NCT04705740` - Influence of the Endoscopists and Endoscopic Retrograde CholangioPanceratography
Recruiting	`NCT04259580` - Calgary Registry for Advanced and Therapeutic Endoscopy
Recruiting	`NCT04291651` - UCSF PANC Cyst Registry
Enrolling by invitation	`NCT03234543` - Remote Ischemic Conditioning in Abdominal Surgery	N/A
Completed	`NCT02916199` - Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method	N/A
Completed	`NCT03717298` - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma	Phase 2
Recruiting	`NCT03334708` - A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting	`NCT05249400` - Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training	N/A
Recruiting	`NCT05824403` - PAncreatic Disease Cohort of TOuLouse
Active, not recruiting	`NCT03269994` - Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?	Phase 3
Enrolling by invitation	`NCT04329039` - Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics	Phase 2/Phase 3
Completed	`NCT03198871` - IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population	Phase 4
Completed	`NCT02337673` - Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
Completed	`NCT01964430` - Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms